Rationale for Correct Answer
The correct answer is: In the phase 3 clinical trial, patients receiving ocrelizumab had significantly less change from baseline in the 25-ft walk test than did those in the placebo group
In a 120-week, placebo-controlled, phase 3 study of ocrelizumab in PPMS, ocrelizumab was associated with significant improvement in several clinical and MRI endpoints, relative to placebo.1 These include fewer patients with increase of ≥1 pt in Expanded Disability Status Scale (EDSS) scores at 12 weeks (primary endpoint) and 24 weeks, decreased change from baseline in 25-foot walk times, reduced volume of hyperintense lesions, and less loss of brain volume. A safety analysis incorporating 7 years of data from clinical trials found ocrelizumab to be well-tolerated with safety outcomes comparable to the general MS population.2
References:
1. Montalban X et al. N Engl J Med. 2017;376:209-220.
2. Hauser SL et al. Neurology. 2021;97:e1546-e1559.